Gemcitabine-resistant Panc89 cells retained the high sensitivity of the parental Panc89 cells to TRAIL–CDK9i, whereas neither TRAIL nor CDK9i alone exerted any significant effects on cancer cell survival (Fig. 4a). This evidence concerns the gene TNFSF10 and cancer.